Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Recs

0
Player Avatar pavlos1971 (99.69) Submitted: 2/26/2013 7:21:29 AM : Outperform Start Price: $159.81 REGN Score: +6.90

This is going to be the year of PCSK9 inhibitors and Regeneron is ahead of others in this game.

Featured Broker Partners


Advertisement